Quek Marcus L, Stein John P, Nichols Peter W, Cai Jie, Miranda Gus, Groshen Susan, Daneshmand Siamak, Skinner Eila C, Skinner Donald G
Departments of Urology, Keck School of Medicine, University of Southern California, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, USA.
J Urol. 2005 Jul;174(1):103-6. doi: 10.1097/01.ju.0000163267.93769.d8.
We determined the prognostic significance of lymphovascular invasion (LVI) in patients treated for invasive transitional cell carcinoma of the bladder with radical cystectomy.
From August 1971 to June 2004, 2,005 patients underwent radical cystectomy for primary bladder cancer with intent to cure. All patients with nontransitional cell carcinoma histology, palliative procedures, unknown lymphovascular status, less than pT1 pathological stage, or any neoadjuvant or adjuvant chemotherapy/radiation therapy were excluded, leaving 702 comprising the study cohort. Of the 702 patients 249 (36%) had LVI.
Median followup was 11.0 years (range 8 days to 23.2 years). Overall 5 and 10-year survival was 51% and 34%, while 5 and 10-year recurrence-free survival was 66% and 64%, respectively. Ten-year recurrence-free survival in patients without LVI was 74% compared with 42% in those with LVI (p <0.0001). Similarly 10-year overall survival was 43% in patients without LVI compared with 18% in those with LVI (p <0.0001). In the organ confined/lymph node negative and lymph node positive pathological subgroups survival outcomes were significantly worse if LVI was present. Although a trend was observed, LVI status was not statistically significant in patients with extravesical node negative disease. Stepwise Cox regression analysis revealed that pathological subgroup (organ confined, extravesical and lymph node positive) (p <0.0001) and LVI status (p = 0.0004) were independent prognostic variables for recurrence-free and overall survival.
Lymphovascular invasion appears to be an important and independent prognostic variable in patients with invasive bladder cancer treated with radical cystectomy. LVI status should be determined in cystectomy specimens, which may provide further risk stratification in patients following radical cystectomy.
我们确定了在接受根治性膀胱切除术治疗的浸润性膀胱移行细胞癌患者中,淋巴管侵犯(LVI)的预后意义。
从1971年8月至2004年6月,2005例患者因原发性膀胱癌接受根治性膀胱切除术以达治愈目的。所有组织学类型为非移行细胞癌、接受姑息性手术、淋巴管状态未知、病理分期小于pT1或接受任何新辅助或辅助化疗/放疗的患者均被排除,最终702例患者组成研究队列。在这702例患者中,249例(36%)存在LVI。
中位随访时间为11.0年(范围8天至23.2年)。总体5年和10年生存率分别为51%和34%,而5年和10年无复发生存率分别为66%和64%。无LVI患者的10年无复发生存率为74%,而有LVI患者为42%(p<0.0001)。同样,无LVI患者的10年总生存率为43%,而有LVI患者为18%(p<0.0001)。在器官局限性/淋巴结阴性和淋巴结阳性的病理亚组中,如果存在LVI,生存结果显著更差。虽然观察到一种趋势,但LVI状态在膀胱外淋巴结阴性疾病患者中无统计学意义。逐步Cox回归分析显示,病理亚组(器官局限性、膀胱外和淋巴结阳性)(p<0.0001)和LVI状态(p = 0.0004)是无复发生存和总生存的独立预后变量。
淋巴管侵犯似乎是接受根治性膀胱切除术治疗的浸润性膀胱癌患者的一个重要且独立的预后变量。应在膀胱切除标本中确定LVI状态,这可能为根治性膀胱切除术后的患者提供进一步的风险分层。